Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acapatamab + enzalutamide
- Development stage
- Discontinued
- Lead developer
- Amgen
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a **combination therapy** consisting of acapatamab, a half-life extended bispecific monoclonal antibody that targets prostate-specific membrane antigen (PSMA) on prostate cancer cells and CD3 on T cells, and enzalutamide, an androgen receptor inhibitor. Acapatamab acts as a T-cell engager to direct immune-mediated killing of prostate cancer cells, while enzalutamide inhibits androgen signaling that drives prostate cancer progression. Acapatamab is being developed and studied primarily for metastatic castration-resistant prostate cancer (mCRPC), particularly in patients refractory to androgen receptor pathway inhibitor therapy and taxane-based chemotherapy. The combination is under evaluation to potentiate antitumor immune activity and androgen deprivation[5].
- Other names
- PSMA × CD3 bispecific T-cell engager + enzalutamideacapatamab + enzalutamide
02
Targets
AR (Adrenergic receptors)CD3 (T-cell surface glycoprotein CD3)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on acapatamab + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acapatamab + enzalutamide.